Summary
After years of a stalled pipeline, 2026 brought two major FDA antibiotic approvals, GSK/Spero Therapeutics’ UTEBZI (tebipenem pivoxil) and Wockhardt’s ZAYNICH (cefepime and zidebactam), signaling real progress against drug-resistant infections.
Resistant bacteria are turning routine infections into medical emergencies, and complicated UTIs are a major flashpoint where standard oral drugs increasingly fail.
Gepotidacin (BLUJEPA), zoliflodacin (NUZOLVENCE), sulopenem etzadroxil/probenecid, and aztreonam-avibactam all expand treatment options for resistant UTIs and gonorrhea.
These approvals offer real hope, but only sustained stewardship, funding, a...
